<DOC>
	<DOCNO>NCT01895257</DOCNO>
	<brief_summary>The investigator propose conduct randomise phase III trial evaluate maintenance strategy compare hepatic arterial injection Yttrium-90 resin microspheres plus continue simplified chemotherapy with/without target therapy versus continue simplified chemotherapy with/without target therapy alone patient dominant exclusive unresectable liver mCRC control 3-6 month chemotherapy induction .</brief_summary>
	<brief_title>Comparing HAI-90Y ( SIR-spheres ) +Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone Treat Colorectal Cancer</brief_title>
	<detailed_description>The aim study investigate whether intensified maintenance treatment SIRT + simplify maintenance chemotherapy benefit term time progression ( TTP ) compare simplify chemotherapy maintenance alone , patient stable disease 3-6 month induction therapy . We would like demonstrate feasibility safety approach investigate strategy potential increase outcome patient . Primary end-point : - Time first progression ( TTP1 overall ) Secondary end-points : - Time global progression ( TTP1 + TTP2 ) , Time second progression ( TTP2 ) , TTP1 liver - Progression Free Survival ( PFS ) - Overall Survival ( OS ) - Safety - Ro resection rate - Quality Life Exploratory analysis : - Prediction evaluation SIR-spheres treatment response ( Belgian centre )</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Inclusion criterion : 1 . Willing able provide write informed consent 2 . Histologically confirm adenocarcinoma colon rectum , without primary tumour situ . Unequivocal measurable ( RECIST 1.1 ) CT evidence liver metastases treatable surgical resection and/or local ablation curative intent time trial entry . 3 . Partial response stable disease ( RECIST 1.1 criterion , control metastatic disease ) chemotherapy induction oxaliplatin and/or irinotecan base induction chemotherapy ( doublet triplet combination ) +/ target therapy 3 6 month . 4 . Trial inclusion must perform 3 6 month since date first course chemotherapy ( induction ) administration . 5 . Limited extrahepatic metastasis lung and/or lymph node permit . Metastases lung must either five nodule number individual nodule 1 cm diameter 1 single lesion 1.7 cm diameter . Involvement lymph node 1 single anatomic region ( pelvis , abdomen chest ) permit provided long diameter measure less 2 cm . 6 . All image evidence use part screen process must within 28 day prior time randomisation . 7 . Suitable either treatment regimen determine clinical assessment undertaken Investigator . 8 . Patients may receive adjuvant chemotherapy ( neo ) adjuvant chemoradiotherapy pelvis , provide last dose chemotherapy administer least 6 month prior begin chemotherapy induction . Previous radiotherapy pelvis exclusion criterion . 9. WHO performance status 0 1 10 . Adequate hematological , renal hepatic function follow : Hematological Neutrophils &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L Renal Creatinine &lt; 1.5 x ULN ( Upper Limit Normal ) Hepatic Bilirubin ≤ 1.0 X ULN Albumin ≥ 30g/L ALT ≤ 5.0 x ULN AST ≤ 5.0 x ULN LDH ≤ 2.5 x ULN The date blood test must within 28 day prior time randomisation . 11 . Age 18 year old . 12 . Female patient must either postmenopausal , sterile ( surgically radiation chemicallyinduced ) , sexually active use acceptable method contraception . 13 . Male patient must surgically sterile sexually active premenopausal partner must use acceptable method contraception . 14 . Life expectancy least 3 month without active treatment . Exclusion criteria 1 . Evidence ascites , cirrhosis , portal hypertension , main portal venous tumour involvement thrombosis determine clinical radiological assessment . 2 . More 6 month since last chemotherapy administration trial inclusion . 3 . Previous radiotherapy deliver upper abdomen . 4 . Nonmalignant disease would render patient unsuitable treatment accord protocol . 5 . Prior major liver resection : remnant liver &lt; 50 % initial liver volume . Patient biliary stent include . 6 . Liver tumor involvement &gt; 80 % study inclusion ( diagnosis trial inclusion patient plan ) . 7 . Resectable metastatic disease trial inclusion . 8 . Progressive disease firstline metastatic chemotherapy . Adjuvant chemotherapy colorectal cancer exclusion criterion provide complete 6 month prior start 1st line chemotherapy . 9 . No oxaliplatin irinotecan use first 3 6 month induction chemotherapy . 10 . Pregnant breast feeding . 11 . Concurrent prior history cancer adequately treat non melanoma skin cancer carcinoma situ cervix . 12 . Severe allergy nonionic contrast agent would prevent contrast medium use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>TTP1</keyword>
	<keyword>TTP2</keyword>
	<keyword>PFS</keyword>
	<keyword>Safety</keyword>
	<keyword>R0 resection rate</keyword>
	<keyword>Quality life</keyword>
	<keyword>Overall Survival</keyword>
</DOC>